Venous sequelae following etomidate.
Five hundred patients receiving one of three different formulations of etomidate were observed on the 2nd and 3rd days after operation for possible venous sequelae. The total frequency of sequelae was 8% or more, the greatest being with the propylene glycol formulation (23%). Formulation of the drug and total dose employed were the most important factors influencing venous sequelae, which were not related to pain on injection.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000771:Anesthesia, Intravenous; D000777:Anesthetics / Q000009:adverse effects; D002626:Chemistry, Pharmaceutical; D002648:Child; D005045:Etomidate / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010689:Phlebitis / Q000139:chemically induced*; D011092:Polyethylene Glycols; D011184:Postoperative Period; D011409:Propylene Glycols; D013924:Thrombophlebitis / Q000139:chemically induced*
D000777:Anesthetics; D007093:Imidazoles; D011409:Propylene Glycols; D011092:Polyethylene Glycols; D005045:Etomidate